Compare OCSL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | PCRX |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2007 | 2010 |
| Metric | OCSL | PCRX |
|---|---|---|
| Price | $11.75 | $23.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $12.63 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 750.9K | 516.5K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | $0.31 | $8.54 |
| P/E Ratio | ★ N/A | $336.29 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $10.63 | $18.80 |
| 52 Week High | $14.77 | $27.64 |
| Indicator | OCSL | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 49.85 |
| Support Level | $10.88 | $22.13 |
| Resistance Level | $13.19 | $24.20 |
| Average True Range (ATR) | 0.28 | 1.02 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 11.89 | 42.93 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.